80 Participants Needed

Netarsudil for Retinal Detachment

HM
JH
Overseen ByJason Hsu, MD
Age: 18+
Sex: Any
Trial Phase: Phase 2 & 3
Sponsor: Wills Eye
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing if the drug netarsudil can safely prevent scar tissue after surgery for a detached retina. It focuses on patients with a high risk of developing scar tissue, which can make recovery harder. The drug works by stopping the cells from forming this problematic scar tissue.

Who Is on the Research Team?

JH

Jason Hsu, MD

Principal Investigator

Wills Eye Physicians-Mid Atlantic Retina, Wills Eye Hospital

Are You a Good Fit for This Trial?

This trial is for adults with a specific type of retinal detachment at high risk for scar tissue formation after surgery. Participants must be willing to follow the study plan and have had no prior significant eye surgeries, except cataract extraction.

Inclusion Criteria

Willing and able to comply with clinic visits and study-related procedures
Able to provide a signed informed consent
A patient must meet the following criteria to be eligible for inclusion in the study: Diagnosed with primary RRD at high risk for PVR development. Specifically, the enrolled eye must include at least 1 but no more than 3 high risk features, which are designated as follows: multiple retinal breaks (3 or more); detachments involving two or more quadrants of the retina; duration of detachment > 3 weeks; vitreous hemorrhage; and choroidal detachment.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either netarsudil or placebo once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56

8 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment, including assessments for proliferative vitreoretinopathy and visual acuity

6 months

What Are the Treatments Tested in This Trial?

Interventions

  • Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
  • Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]
Trial Overview The study tests if netarsudil can prevent scar tissue in eyes at risk after retinal detachment repair. Patients will receive netarsudil or a control solution post-surgery to see which is more effective in preventing proliferative vitreoretinopathy.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Netarsudil 0.02%Experimental Treatment1 Intervention
Group II: Artificial tearsPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Wills Eye

Lead Sponsor

Trials
81
Recruited
15,400+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security